Robert Tighe has served as the Chief Scientific Officer since July 2023. Mr. Tighe has extensive experience in immuno-oncology (IO) drug discovery & development. He has broad scientific, technical and managerial expertise that spans early discovery (target validation, candidate screening) to IND-enablement (toxicology, DMPK, preclinical efficacy, mechanism-of-action) through early clinical development (IND preparation/authorship, regulatory affairs, clinical CRO selection, biomarker assays).
With over 27 years of research experience (17 years of them in IO), Mr. Tighe has a proven track record of success in moving novel immunotherapies into the clinic as a major contributor to 5 successful INDs including the NHS-IL12 immunocytokine, the approved anti-PD-L1 antibody Bavencio™, M7824 (anti-PD-L1-TGFb-Trap), CTX-471 (novel, differentiated CD137 agonist), and TC-510 (mesothelin-targeted autologous TRuC T cell therapy enhanced by a PD-1xCD28 chimeric switch receptor). Mr. Tighe completed his undergraduate training at Salem State College and has attended the Harvard University Extension School, the International Management Program at Merck, KGaA, and has a certificate in executive leadership from Cornell University.